A049960 Stock Overview
A biotechnology company, develops lactic acid bacteria products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Cell Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,900.00 |
| 52 Week High | ₩16,950.00 |
| 52 Week Low | ₩11,170.00 |
| Beta | 0.66 |
| 1 Month Change | -2.05% |
| 3 Month Change | -8.51% |
| 1 Year Change | 11.79% |
| 3 Year Change | -23.67% |
| 5 Year Change | -9.15% |
| Change since IPO | 330.00% |
Recent News & Updates
We Think That There Are Some Issues For Cell Biotech (KOSDAQ:049960) Beyond Its Promising Earnings
Mar 27
Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings
Aug 24Recent updates
We Think That There Are Some Issues For Cell Biotech (KOSDAQ:049960) Beyond Its Promising Earnings
Mar 27Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings
Aug 24Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their Portfolio
May 05Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?
Mar 18A Look At Cell Biotech's (KOSDAQ:049960) Share Price Returns
Feb 25Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% Dividend
Feb 04
Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?
Jan 14Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-Dividend
Dec 24Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Dec 13Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five Years
Nov 18Shareholder Returns
| A049960 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 6.0% | -0.2% | -1.0% |
| 1Y | 11.8% | 16.7% | -11.5% |
Return vs Industry: A049960 underperformed the KR Biotechs industry which returned 16.7% over the past year.
Return vs Market: A049960 exceeded the KR Market which returned -11.5% over the past year.
Price Volatility
| A049960 volatility | |
|---|---|
| A049960 Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.5% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A049960 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A049960's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 111 | Myung-Jun Jung | www.cellbiotech.com |
Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally. It engages in the probiotics, microbiome, and anticancer new drug businesses. The company sells its products through partnerships with multinational companies and local retailers under the DUOLAC, DUOLAB, LACTOClear, and LAB2PRO brand names.
Cell Biotech Co., Ltd. Fundamentals Summary
| A049960 fundamental statistics | |
|---|---|
| Market cap | ₩87.88b |
| Earnings (TTM) | ₩15.13b |
| Revenue (TTM) | ₩49.91b |
5.8x
P/E Ratio1.8x
P/S RatioIs A049960 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A049960 income statement (TTM) | |
|---|---|
| Revenue | ₩49.91b |
| Cost of Revenue | ₩14.10b |
| Gross Profit | ₩35.81b |
| Other Expenses | ₩20.68b |
| Earnings | ₩15.13b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.21k |
| Gross Margin | 71.75% |
| Net Profit Margin | 30.31% |
| Debt/Equity Ratio | 0% |
How did A049960 perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield20%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 09:19 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cell Biotech Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Young Ok Kim | DAOL Investment & Securities Co., Ltd. |
| Hyuk Jin Yoon | Eugene Investment & Securities Co Ltd. |
| Tae Hyun Kim | IBK Securities Co. Ltd. |